Chronic immune-related adverse events occur commonly in melanoma patients treated with adjuvant anti–PD-1 therapy, according to findings highlighted by The ASCO Post. The report lands at a moment when adjuvant checkpoint inhibition has become standard practice for resected high-risk melanoma, and clinicians are still learning what months and years of downstream toxicity look like.

That gap matters. Adjuvant anti–PD-1 agents — the class that includes pembrolizumab and nivolumab — transformed outcomes for stage III melanoma after surgical resection, but the approval trials captured adverse events within defined treatment and follow-up windows. Chronic, persistent toxicities that emerge or linger beyond those windows are harder to count. The ASCO Post report points squarely at that blind spot, and its headline verdict — "common" — should prompt a recalibration of how dermatologists and oncologists counsel patients before starting therapy.

Why does this matter for dermatology?

Skin is among the most frequent targets of immune-related toxicity. Immune checkpoint inhibitors can produce:

• vitiligo
• psoriasiform eruptions
• eczematous dermatitis
• pruritus and lichenoid reactions
• bullous eruptions in rarer cases

When these events become chronic rather than self-limited, they shift from a nuisance to a long-term management problem. Patients cleared of melanoma may then carry inflammatory skin disease that requires ongoing topical or systemic therapy, sometimes for years.

The takeaway: for melanoma survivors on anti–PD-1 therapy, skin surveillance shouldn't stop when the drug does.

What should clinicians watch going forward?

The report's framing suggests the burden of chronic immune-related adverse events is not marginal. That has practical consequences for shared decision-making in the adjuvant setting, where treatment intent is preventive rather than therapeutic, and where patients weigh recurrence risk against years of possible immune-mediated morbidity.

It also raises documentation questions. Chronic irAEs that persist beyond a year — the conventional threshold many trials use to define "chronic" — may be undercaptured in standard follow-up, and underreported in registries that feed back into guideline writing.

The one-sentence takeaway: adjuvant anti–PD-1 therapy in melanoma carries a common risk of chronic immune-related adverse events, and the field will need longer toxicity horizons — and firmer dermatology involvement — to quantify and manage it properly.